Heath Ministry secures 300 million covid vaccine doses from Biological-E
In India, Biological-E plans to conduct a clinical study of Providence's vaccine and apply for emergency use authorisation.
The Union ministry of health and family welfare stated on Thursday that the Centre has concluded agreements with Hyderabad-based vaccine maker Biological-E to secure 300 million Covid-19 vaccine doses.
The vaccine, which is presently conducting phase 3 clinical testing, is expected to be accessible in the next months, according to the health ministry.
In India, Biological-E plans to conduct a clinical study of Providence's vaccine and apply for emergency use authorisation.
On Tuesday, Biological E. announced that it had entered into a licensing deal with Providence Therapeutics Holdings to produce the Canadian company's mRNA Covid-19 vaccine in India.
The company also has a different contract to manufacture approximately 600 million doses of Johnson & Johnson's Covid-19 shot every year.
Since the pre-clinical stage, the Indian government has backed the vaccine candidate. The Department of Biotechnology has teamed up with Biological-E to execute all animal challenge and assay studies through its Research Institute Translational Health Science Technology Institute in Faridabad (Haryana), in addition to providing financial assistance in the form of grant-in-aid of above Rs 100 crores.
The assistance is part of the Indian government's "Mission COVID Suraksha- the Indian COVID-19 Vaccine Development Mission," which seeks to develop a safe, efficacious, inexpensive, and accessible Covid-19 vaccine, according to the ministry.
The agreement with M/s Biological-E is part of the Government of India's larger effort to promote indigenous vaccine makers by granting them with research and development (R&D) assistance as well as financial assistance.
For breaking news and live news updates, like us on Facebook or follow us on Twitter and Instagram. Read more on Latest Health News on The National Bulletin